The efficacy of HDAC inhibitors in neoplasm treatment

Psiuk Dominika, Rocka Agata, Żak Klaudia, Tomczyk Żaklina, Filip Agata. The efficacy of HDAC inhibitors in neoplasm treatment. Journal of Education, Health and Sport. 2020;10(8):244-250. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.08.028

https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.08.028

https://zenodo.org/record/3987520

 

 

 

 

 

 

 

 

 

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

© The Authors 2020;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

 

Received: 01.08.2020. Revised: 05.08.2020. Accepted: 17.08.2020.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The efficacy of HDAC inhibitors in neoplasm treatment

 

Dominika Psiuk¹, Agata Rocka¹, Klaudia Żak¹, Żaklina Tomczyk¹, Agata Filip²

 

¹Student Research Group, Department of Cancer Genetics, Medical University of Lublin, Radziwillowska 11, 20-080 Lublin, Poland, tel. +48 81 4486102

²Head of the Department of Cancer Genetics, Medical University of Lublin, Radziwillowska 11, 20-080 Lublin, Poland, tel. +48 81 4486102

 

Dominika Psiuk: ORCID:0000-0003-3319-3489; dominika.psiuk@gmail.com
Agata Rocka: ORCID:0000-0003-4738-3160;  agatarocka2@gmail.com
Klaudia Żak:  ORCID:0000-0003-2421-2553; zakklaudia3@gmail.com
Żaklina Tomczyk: ORCID:0000-0002-0251-0448; zaklinka512@gmail.com
Agata Filip: ORCID: 0000-0001-7591-5887; agata.filip@umlub.pl

 

Abstract

Introduction and purpose: Histone Deacetylases (HDACs) are associated with epigenetic regulation of gene expression. They are responsible of adequate action of not only histone proteins, but also crucial cell cycle proteins, such as p53, NF‐κB or alpha tubulin. Recent studies have shown the connection between expression of HDAC and carcinogenesis and impact of HDAC inhibitors on cancer therapy. The aim of the study was to review the recent  studies on HDAC inhibitors efficiency in the treatment of hematologic neoplasms and solid tumors. It is a study review from 2010 to 2020 using the PubMed database and ClinicalTrials.gov.

 

 

Description of state of knowledge: Most studies related to HDAC inhibitors impact in hematological neoplasms, such as multiple myeloma, Hodgkin lymphoma, T-cell lymphomas and acute myeloid leukemia. Among studied agents panobinostat, vorinostat and showed efficacy. Moreover, some HDACi demonstrated effectiveness in solid tumors treatment, foremost vorinostat in breast cancer and entinostat in non-small cell lung lymphoma.

Summary: Including HDAC inhibitors in tumor treatment could be beneficial for patients, especially those with advanced, relapsed or refractory hematologic neoplasm. However, further  studies are necessary to confirm their efficacy and to reveal side effects.

 

Key words: HDAC, inhibitors, cancer, hematology